{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:41:18Z","timestamp":1759160478820,"version":"3.43.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,13]]},"DOI":"10.7759\/cureus.90016","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T21:09:37Z","timestamp":1755119377000},"source":"Crossref","is-referenced-by-count":1,"title":["Refractory Hypophosphatemia Secondary to Tumor-Induced Osteomalacia: Diagnostic Challenges and Successful Management With Burosumab"],"prefix":"10.7759","author":[{"given":"Amna","family":"Ramzan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad Aftab Khan","family":"Lodhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Ramzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola S","year":"2017","unstructured":"Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella SH, Collins MT. Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017, 3:17044. 10.1038\/nrdp.2017.44","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab099","article-title":"Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience","volume":"5","author":"Dahir K","year":"2021","unstructured":"Dahir K, Zanchetta MB, Stanciu I, et al.. Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc. 2021, 5:bvab099. 10.1210\/jendso\/bvab099","journal-title":"J Endocr Soc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi ML","year":"2021","unstructured":"Brandi ML, Clunie GP, Houillier P, Jan de Beur SM, Minisola S, Oheim R, Seefried L. Challenges in the management of tumor-induced osteomalacia (TIO). Bone. 2021, 152:116064. 10.1016\/j.bone.2021.116064","journal-title":"Bone"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis","volume":"87","author":"Schaefer B","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, Zoller H. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol. 2021, 87:2256-73. 10.1111\/bcp.14643","journal-title":"Br J Clin Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","volume":"2015","author":"Hardy S","year":"2015","unstructured":"Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015, 2015:468675. 10.1155\/2015\/468675","journal-title":"Int J Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf M","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013, 28:1793-803. 10.1002\/jbmr.1923","journal-title":"J Bone Miner Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-022-01005-8","article-title":"Tumor-induced osteomalacia: a systematic clinical review of 895 cases","volume":"111","author":"Bosman A","year":"2022","unstructured":"Bosman A, Palermo A, Vanderhulst J, et al.. Tumor-induced osteomalacia: a systematic clinical review of 895 cases. Calcif Tissue Int. 2022, 111:367-79. 10.1007\/s00223-022-01005-8","journal-title":"Calcif Tissue Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0552","article-title":"Tumor-induced osteomalacia: experience from three tertiary care centers in India","volume":"8","author":"Pal R","year":"2019","unstructured":"Pal R, Bhadada SK, Singhare A, et al.. Tumor-induced osteomalacia: experience from three tertiary care centers in India. Endocr Connect. 2019, 8:266-76. 10.1530\/EC-18-0552","journal-title":"Endocr Connect"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2052","article-title":"(68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia","volume":"101","author":"El-Maouche D","year":"2016","unstructured":"El-Maouche D, Sadowski SM, Papadakis GZ, et al.. (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2016, 101:3575-81. 10.1210\/jc.2016-2052","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07342-2","article-title":"Diagnostic efficiency of (68)Ga-DOTANOC PET\/CT in patients with suspected tumour-induced osteomalacia","volume":"31","author":"He Q","year":"2021","unstructured":"He Q, Zhang B, Zhang L, et al.. Diagnostic efficiency of (68)Ga-DOTANOC PET\/CT in patients with suspected tumour-induced osteomalacia. Eur Radiol. 2021, 31:2414-21. 10.1007\/s00330-020-07342-2","journal-title":"Eur Radiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur SM","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, et al.. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. 2021, 36:627-35. 10.1002\/jbmr.4233","journal-title":"J Bone Miner Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna KL","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, et al.. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018, 33:1383-93. 10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23","volume":"61","author":"Bergwitz C","year":"2010","unstructured":"Bergwitz C, J\u00fcppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010, 61:91-104. 10.1146\/annurev.med.051308.111339","journal-title":"Annu Rev Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2012.02.027","article-title":"Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease","volume":"318","author":"Quarles LD","year":"2012","unstructured":"Quarles LD. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res. 2012, 318:1040-8. 10.1016\/j.yexcr.2012.02.027","journal-title":"Exp Cell Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0239","article-title":"Interactions between FGF23 and vitamin D","volume":"11","author":"Razzaque MS","year":"2022","unstructured":"Razzaque MS. Interactions between FGF23 and vitamin D. Endocr Connect. 2022, 11:10.1530\/EC-22-0239","journal-title":"Endocr Connect"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.05.045","article-title":"The role of vitamin D receptor mutations in the development of alopecia","volume":"347","author":"Malloy PJ","year":"2011","unstructured":"Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011, 347:90-6. 10.1016\/j.mce.2011.05.045","journal-title":"Mol Cell Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf040","article-title":"Gallium-68-DOTATATE PET\/CT for phosphaturic mesenchymal tumor localization in suspected tumor-induced osteomalacia","volume":"9","author":"Hoong CW","year":"2025","unstructured":"Hoong CW, Sfeir JG, Drake MT, Broski SM. Gallium-68-DOTATATE PET\/CT for phosphaturic mesenchymal tumor localization in suspected tumor-induced osteomalacia. JBMR Plus. 2025, 9:ziaf040. 10.1093\/jbmrpl\/ziaf040","journal-title":"JBMR Plus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/394885-refractory-hypophosphatemia-secondary-to-tumor-induced-osteomalacia-diagnostic-challenges-and-successful-management-with-burosumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T21:09:37Z","timestamp":1755119377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/394885-refractory-hypophosphatemia-secondary-to-tumor-induced-osteomalacia-diagnostic-challenges-and-successful-management-with-burosumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.90016","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}